AI Summary & Key Takeaways
AI InsightFurther studies should be conducted to evaluate their potential use as biomarkers in STEMI cases.
📌 3 Key Takeaways
Abstract
Objective: The aim of this study was to evaluate the expression levels of cardiac-related circulating microRNAs (miRNAs) in ST-elevation myocardial infarction (STEMI) patients.Methods: This study has a prospective experimental cohort design. A total of 12 consecutive patients with acute chest pain within 12 h admitted to emergency department (STEMI group) and 13 adult patients with normal coronary angiography during the same period were enrolled (control group) in this study. Changes in the expression of miR-122, miR-208, miR-375, miR-22, miR-133b, miR-92b, miR-21, miR-133a, miR-423-5p, miR-27b, miR-30a-3p, miR-17, miR-30d, miR-642, and miR-95 were analyzed using quantitative reverse transcription-polymerase chain reaction. Blood samples were collected before angiography and 24 h after angiography. Data were analyzed using the Statistical Package for the Social Sciences v19.Results: The STEMI group included 12 patients (7 males) with an average age of 56.5±8.3 (range, 44-69) years. The control group included 13 patients (9 males) with an average age of 59±11 (range, 42-80) years. When fold differences were calculated for the miRNA expression values, only miR-30d and miR-423-5p expression levels in STEMI patients showed significant differences in expression levels compared with control patients. The miRNA levels were 2.3-fold higher for miR-30d (p=0.034) and 6.9-fold higher for miR-423-5p (p=0.017). There was no significant correlation between troponin I and miR-30d or miR-423-5p levels (p>0.05).Conclusion: In this study, the expression levels of miRNAs related to cardiac disease were evaluated in peripheral blood. The circulating miR423-5p and miR-30d levels in peripheral blood were found to be higher in STEMI cases than in the control group. Further studies should be conducted to evaluate their potential use as biomarkers in STEMI cases.